Correction: Gjyshi et al., "Activated Nrf2 interacts with Kaposi's sarcoma-associated herpesvirus latency protein LANA-1 and host protein KAP1 to mediate global lytic gene repression." [Journal of Virology, 89, 15, (2015), (7874-7892)] doi: 10.1128/JVI.00895-15;Activated Nrf2 interacts with Kaposi's sarcoma-associated herpesvirus latency protein LANA-1 and host protein KAP1 to mediate global lytic gene repression

Journal of Virology

Volumn 89, Issue 15, 2015, Pages 7874-7892

  Gjyshi, Olsi ^a   Roy, Arunava ^a   Dutta, Sujoy ^a   Veettil, Mohanan Valiya ^a   Dutta, Dipanjan ^a   Chandran, Bala ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUSATOL; CYCLOOXYGENASE 2; KRUPPEL ASSOCIATED BOX ASSOCIATED PROTEIN 1; LATENCY ASSOCIATED NUCLEAR ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN 1; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROTEIN KINASE C ZETA; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; IMMEDIATE EARLY PROTEIN; LATENCY-ASSOCIATED NUCLEAR ANTIGEN; NFE2L2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN BINDING; RTA PROTEIN, HUMAN HERPESVIRUS 8; TRANSACTIVATOR PROTEIN; TRIM28 PROTEIN, HUMAN; VIRUS ANTIGEN;

ARTICLE; CARCINOGENESIS; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE REPRESSION; GENE SILENCING; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; KAP1 GENE; LANA 1 GENE; LYMPHOMA CELL LINE; NEXT GENERATION SEQUENCING; NONHUMAN; NRF2 GENE; OPEN READING FRAME; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REPRESSOR GENE; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; UPREGULATION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS REACTIVATION; DOWN REGULATION; GENETICS; KAPOSI SARCOMA; METABOLISM; VIROLOGY;

HUMAN HERPESVIRUS 8; LANA;

ANTIGENS, VIRAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 8, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; LYMPHOMA, PRIMARY EFFUSION; NF-E2-RELATED FACTOR 2; NUCLEAR PROTEINS; PROTEIN BINDING; REPRESSOR PROTEINS; SARCOMA, KAPOSI; TRANS-ACTIVATORS;

EID: 84937714757     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01634-17     Document Type: Erratum

References (65)

1. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186-1191. http://dx.doi.org/10.1056/NEJM199505043321802.
2. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869. http://dx.doi.org/10.1126/science.7997879.
3. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay MF, Clauvel JP, Raphael M, Degos L, Sigaux F. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276-1280.
4. Costa J, Rabson AS. 1983. Generalised Kaposi's sarcoma is not a neoplasm. Lancet i:58.
5. Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, Knowles DM, Garber R, Pellett PE, McGeoch DJ, Chang Y. 1996. Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol 70:549-558.
6. Okada S, Goto H, Yotsumoto M. 2014. Current status of treatment for primary effusion lymphoma. Intractable Rare Dis Res 3:65-74. http://dx.doi.org/10.5582/irdr.2014.01010.
7. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes D, Ganem D. 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 2:342-346. http://dx.doi.org/10.1038/nm0396-342.
8. Miller G, Heston L, Grogan E, Gradoville L, Rigsby M, Sun R, Shedd D, Kushnaryov VM, Grossberg S, Chang Y. 1997. Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol 71:314-324.
9. Krishnan HH, Naranatt PP, Smith MS, Zeng L, Bloomer C, Chandran B. 2004. Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcomaassociated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol 78:3601-3620. http://dx.doi.org/10.1128/JVI.78.7.3601-3620.2004.
10. Toth Z, Maglinte DT, Lee SH, Lee HR, Wong LY, Brulois KF, Lee S, Buckley JD, Laird PW, Marquez VE, Jung JU. 2010. Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog 6:e1001013. http://dx.doi.org/10.1371/journal.ppat.1001013.
11. Gunther T, Grundhoff A. 2010. The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathog 6:e1000935. http://dx.doi.org/10.1371/journal.ppat.1000935.
12. Toth Z, Brulois K, Jung JU. 2013. The chromatin landscape of Kaposi's sarcoma-associated herpesvirus. Viruses 5:1346-1373. http://dx.doi.org/10.3390/v5051346.
13. DeWire SM, Damania B. 2005. The latency-associated nuclear antigen of rhesus monkey rhadinovirus inhibits viral replication through repression of Orf50/Rta transcriptional activation. J Virol 79:3127-3138. http://dx.doi.org/10.1128/JVI.79.5.3127-3138.2005.
14. Lu F, Day L, Gao SJ, Lieberman PM. 2006. Acetylation of the latencyassociated nuclear antigen regulates repression of Kaposi's sarcomaassociated herpesvirus lytic transcription. J Virol 80:5273-5282. http://dx.doi.org/10.1128/JVI.02541-05.
15. Cai Q, Cai S, Zhu C, Verma SC, Choi JY, Robertson ES. 2013. A unique SUMO-2-interacting motif within LANA is essential for KSHV latency. PLoS Pathog 9:e1003750. http://dx.doi.org/10.1371/journal.ppat.1003750.
16. Sun R, Liang D, Gao Y, Lan K. 2014. Kaposi's sarcoma-associated herpesvirus-encoded LANA interacts with host KAP1 to facilitate establishment of viral latency. J Virol 88:7331-7344. http://dx.doi.org/10.1128/JVI.00596-14.
17. Nguyen T, Nioi P, Pickett CB. 2009. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284:13291-13295. http://dx.doi.org/10.1074/jbc.R900010200.
18. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M. 2004. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24:7130-7139. http://dx.doi.org/10.1128/MCB.24.16.7130-7139.2004.
19. Apopa PL, He X, Ma Q. 2008. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J Biochem Mol Toxicol 22:63-76. http://dx.doi.org/10.1002/jbt.20212.
20. Bloom DA, Jaiswal AK. 2003. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response elementmediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem 278:44675-44682. http://dx.doi.org/10.1074/jbc.M307633200.
21. Nioi P, McMahon M, Itoh K, Yamamoto M, Hayes JD. 2003. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem J 374:337-348. http://dx.doi.org/10.1042/BJ20030754.
22. Yu R, Chen C, Mo YY, Hebbar V, Owuor ED, Tan TH, Kong AN. 2000. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J Biol Chem 275:39907-39913. http://dx.doi.org/10.1074/jbc.M004037200.
23. Niture SK, Jaiswal AK. 2012. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem 287:9873-9886. http://dx.doi.org/10.1074/jbc.M111.312694.
24. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM, Ku SK, Jung Y, Kwak MK. 2011. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Cancer Res 71: 2260-2275. http://dx.doi.org/10.1158/0008-5472.CAN-10-3007.
25. Zhou S, Ye W, Zhang M, Liang J. 2012. The effects of nrf2 on tumor angiogenesis: a review of the possible mechanisms of action. Crit Rev Eukaryot Gene Expr 22:149-160. http://dx.doi.org/10.1615/CritRevEukarGeneExpr.v22.i2.60.
26. Pan H, Wang H, Zhu L, Mao L, Qiao L, Su X. 2013. The role of nrf2 in migration and invasion of human glioma cell u251. World Neurosurg 80:363-370. http://dx.doi.org/10.1016/j.wneu.2011.06.063.
27. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H. 2012. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22:66-79. http://dx.doi.org/10.1016/j.ccr.2012.05.016.
28. Hayashi A, Suzuki H, Itoh K, Yamamoto M, Sugiyama Y. 2003. Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem Biophys Res Commun 310:824-829. http://dx.doi.org/10.1016/j.bbrc.2003.09.086.
29. Maher JM, Dieter MZ, Aleksunes LM, Slitt AL, Guo G, Tanaka Y, Scheffer GL, Chan JY, Manautou JE, Chen Y, Dalton TP, Yamamoto M, Klaassen CD. 2007. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology 46:1597-1610. http://dx.doi.org/10.1002/hep.21831.
30. Gjyshi O, Bottero V, Veettil MV, Dutta S, Singh VV, Chikoti L, Chandran B. 2014. Kaposi's sarcoma-associated herpesvirus induces Nrf2 during de novo infection of endothelial cells to create a microenvironment conducive to infection. PLoS Pathog 10:e1004460. http://dx.doi.org/10.1371/journal.ppat.1004460.
31. No JH, Kim YB, Song YS. 2014. Targeting nrf2 signaling to combat chemoresistance. J Cancer Prev 19:111-117. http://dx.doi.org/10.15430/JCP.2014.19.2.111.
32. Gjyshi O, Flaherty S, Veettil MV, Johnson KE, Chandran B, Bottero V. 2015. Kaposi's sarcoma-associated herpesvirus induces Nrf2 activation in latently infected endothelial cells through SQSTM1 phosphorylation and interaction with polyubiquitinated Keap1. J Virol 89:2268-2286. http://dx.doi.org/10.1128/JVI.02742-14.
33. Nun TK, Kroll DJ, Oberlies NH, Soejarto DD, Case RJ, Piskaut P, Matainaho T, Hilscher C, Wang L, Dittmer DP, Gao SJ, Damania B. 2007. Development of a fluorescence-based assay to screen antiviral drugs against Kaposi's sarcoma associated herpesvirus. Mol Cancer Ther 6:2360-2370. http://dx.doi.org/10.1158/1535-7163.MCT-07-0108.
34. An FQ, Folarin HM, Compitello N, Roth J, Gerson SL, McCrae KR, Fakhari FD, Dittmer DP, Renne R. 2006. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcomaassociated herpesvirus latency in vitro and in vivo. J Virol 80:4833-4846. http://dx.doi.org/10.1128/JVI.80.10.4833-4846.2006.
35. Vart RJ, Nikitenko LL, Lagos D, Trotter MW, Cannon M, Bourboulia D, Gratrix F, Takeuchi Y, Boshoff C. 2007. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res 67:4042-4051. http://dx.doi.org/10.1158/0008-5472.CAN-06-3321.
36. Zhu L, Wang R, Sweat A, Goldstein E, Horvat R, Chandran B. 1999. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K81A, and K81B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells. Virology 256: 381-392. http://dx.doi.org/10.1006/viro.1999.9674.
37. Purushothaman P, Thakker S, Verma SC. 2015. Transcriptome analysis of Kaposi's sarcoma-associated herpesvirus during de novo primary infection of human B and endothelial cells. J Virol 89:3093-3111. http://dx.doi.org/10.1128/JVI.02507-14.
38. Ye J, Shedd D, Miller G. 2005. An Sp1 response element in the Kaposi's sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle induction by butyrate. J Virol 79:1397-1408. http://dx.doi.org/10.1128/JVI.79.3.1397-1408.2005.
39. Sarek G, Jarviluoma A, Ojala PM. 2006. KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood 107:725-732. http://dx.doi.org/10.1182/blood-2005-06-2534.
40. Paul AG, Chandran B, Sharma-Walia N. 2013. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies. Transl Res 162:77-92. http://dx.doi.org/10.1016/j.trsl.2013.03.004.
41. Coscoy L. 2007. Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat Rev Immunol 7:391-401. http://dx.doi.org/10.1038/nri2076.
42. Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, Zhang DD. 2011. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci USA 108:1433-1438. http://dx.doi.org/10.1073/pnas.1014275108.
43. Maruyama A, Nishikawa K, Kawatani Y, Mimura J, Hosoya T, Harada N, Yamamato M, Itoh K. 2011. The novel Nrf2-interacting factor KAP1 regulates susceptibility to oxidative stress by promoting the Nrf2-mediated cytoprotective response. Biochem J 436:387-397. http://dx.doi.org/10.1042/BJ20101748.
44. Paudel N, Sadagopan S, Chakraborty S, Sarek G, Ojala PM, Chandran B. 2012. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with multifunctional angiogenin to utilize its antiapoptotic functions. J Virol 86:5974-5991. http://dx.doi.org/10.1128/JVI.00070-12.
45. Cheng CT, Kuo CY, Ann DK. 2014. KAPtain in charge of multiple missions: emerging roles of KAP1. World J Biol Chem 5:308-320. http://dx.doi.org/10.4331/wjbc.v5.i3.308.
46. Geismann C, Arlt A, Sebens S, Schafer H. 2014. Cytoprotection "gone astray": Nrf2 and its role in cancer. Onco Targets Ther 7:1497-1518. http://dx.doi.org/10.2147/OTT.S36624.
47. Petre CE, Sin SH, Dittmer DP. 2007. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol 81:1912-1922. http://dx.doi.org/10.1128/JVI.01757-06.
48. Li X, Feng J, Sun R. 2011. Oxidative stress induces reactivation of Kaposi's sarcoma-associated herpesvirus and death of primary effusion lymphoma cells. J Virol 85:715-724. http://dx.doi.org/10.1128/JVI.01742-10.
49. Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, Yamamoto M. 2001. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 6:857-868. http://dx.doi.org/10.1046/j.1365-2443.2001.00469.x.
50. Zhu M, Fahl WE. 2001. Functional characterization of transcription regulators that interact with the electrophile response element. Biochem Biophys Res Commun 289:212-219. http://dx.doi.org/10.1006/bbrc.2001.5944.
51. Ohta K, Ohigashi M, Naganawa A, Ikeda H, Sakai M, Nishikawa J, Imagawa M, Osada S, Nishihara T. 2007. Histone acetyltransferase MOZ acts as a co-activator of Nrf2-MafK and induces tumour marker gene expression during hepatocarcinogenesis. Biochem J 402:559-566. http://dx.doi.org/10.1042/BJ20061194.
52. Lim C, Gwack Y, Hwang S, Kim S, Choe J. 2001. The transcriptional activity of cAMP response element-binding protein-binding protein is modulated by the latency associated nuclear antigen of Kaposi's sarcomaassociated herpesvirus. J Biol Chem 276:31016-31022. http://dx.doi.org/10.1074/jbc.M102431200.
53. Chang PC, Fitzgerald LD, Van Geelen A, Izumiya Y, Ellison TJ, Wang DH, Ann DK, Luciw PA, Kung HJ. 2009. Kruppel-associated box domain-associated protein-1 as a latency regulator for Kaposi's sarcoma-associated herpesvirus and its modulation by the viral protein kinase. Cancer Res 69:5681-5689. http://dx.doi.org/10.1158/0008-5472.CAN-08-4570.
54. Zhang L, Zhu C, Guo Y, Wei F, Lu J, Qin J, Banerjee S, Wang J, Shang H, Verma SC, Yuan Z, Robertson ES, Cai Q. 2014. Inhibition of KAP1 enhances hypoxia-induced Kaposi's sarcoma-associated herpesvirus reactivation through RBP-Jkappa. J Virol 88:6873-6884. http://dx.doi.org/10.1128/JVI.00283-14.
55. Sharma-Walia N, Patel K, Chandran K, Marginean A, Bottero V, Kerur N, Paul AG. 2012. COX-2/PGE2: molecular ambassadors of Kaposi's sarcoma-associated herpes virus oncoprotein-v-FLIP. Oncogenesis 1:e5. http://dx.doi.org/10.1038/oncsis.2012.5.
56. Sharma-Walia N, Paul AG, Bottero V, Sadagopan S, Veettil MV, Kerur N, Chandran B. 2010. Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog 6:e1000777. http://dx.doi.org/10.1371/journal.ppat.1000777.
57. Sharma-Walia N, Raghu H, Sadagopan S, Sivakumar R, Veettil MV, Naranatt PP, Smith MM, Chandran B. 2006. Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. J Virol 80:6534-6552. http://dx.doi.org/10.1128/JVI.00231-06.
58. Shelby BD, LaMarca HL, McFerrin HE, Nelson AB, Lasky JA, Sun G, Myatt L, Offermann MK, Morris CA, Sullivan DE. 2007. Kaposi's sarcoma associated herpesvirus G-protein coupled receptor activation of cyclooxygenase-2 in vascular endothelial cells. Virol J 4:87. http://dx.doi.org/10.1186/1743-422X-4-87.
59. Paul AG, Chandran B, Sharma-Walia N. 2013. Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines. Transl Res 161:447-468. http://dx.doi.org/10.1016/j.trsl.2013.02.008.
60. Paul AG, Sharma-Walia N, Chandran B. 2011. Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma. PLoS One 6:e24379. http://dx.doi.org/10.1371/journal.pone.0024379.
61. Gjyshi O, Chandran B. 2015. Manipulating host signaling for pathogenic purposes: hijacking of the transcriptional activity of the host protein Nrf2 by Kaposi's sarcoma-associated herpesvirus. Sci Proc 2:e599. http://dx.doi.org/10.14800/sp.599.
62. Paul AG, Sharma-Walia N, Kerur N, White C, Chandran B. 2010. Piracy of prostaglandin E2/EP receptor-mediated signaling by Kaposi's sarcomaassociated herpes virus (HHV-8) for latency gene expression: strategy of a successful pathogen. Cancer Res 70:3697-3708. http://dx.doi.org/10.1158/0008-5472.CAN-09-3934.
63. Wu T, Harder BG, Wong PK, Lang JE, Zhang DD. 23 August 2014. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?. Mol Carcinog http://dx.doi.org/10.1002/mc.22202.
64. Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, Zhang DD. 2014. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res 74:7430-7441. http://dx.doi.org/10.1158/0008-5472.CAN-14-1439.
65. Olayanju A, Copple IM, Bryan HK, Edge GT, Sison RL, Wong MW, Lai ZQ, Lin ZX, Dunn K, Sanderson CM, Alghanem AF, Cross MJ, Ellis EC, Ingelman-Sundberg M, Malik HZ, Kitteringham NR, Goldring CE, Park BK. 2015. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. Free Radic Biol Med 78: 202-212. http://dx.doi.org/10.1016/j.freeradbiomed.2014.11.003.